Evercore analyst Gavin Clark-Gartner maintains $Mirum Pharmaceuticals (MIRM.US)$ with a buy rating, and adjusts the target price from $66 to $68.
According to TipRanks data, the analyst has a success rate of 52.5% and a total average return of 25.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Mirum Pharmaceuticals (MIRM.US)$'s main analysts recently are as follows:
Mirum Pharmaceuticals' recent financial disclosure for Q3 surpassed market expectations, primarily driven by robust Livmarli sales. Although certain reimbursement factors may have advanced some of this revenue, the continued upward trajectory of Livmarli's launch is promising, contributing increasingly to the overall franchise sales.
Mirum Pharmaceuticals recorded a substantial performance that surpassed expectations, primarily fueled by the success of Livmarli. This has resulted in an upward revision of their financial guidance for FY2024, exceeding the initial high-end projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
